Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six‐month, randomized, double‐blind, placebo‐controlled, proof‐of‐concept pilot study at a single center

Objective To better understand the feasibility of using imatinib, a tyrosine kinase inhibitor, to treat active diffuse cutaneous systemic sclerosis (dcSSc). Methods We performed a 6‐month, randomized, double‐blind, placebo‐controlled, proof‐of‐concept pilot study of imatinib in patients with acti…